Nature of the Event

Evonile Pharma Limited is undertaking a rights issue of partly paid-up equity shares as approved by the Board on October 8, 2026 and Rights Issue Committee on November 4, 2026.

Key Quantitative Figures

  • Issue Size: Up to 10,287,832 equity shares of face value ₹5 each
  • Issue Price: ₹860 per share (including premium of ₹855)
  • Total Amount: ₹8,847.54 million (₹884.75 crore)
  • Rights Ratio: 5 rights shares for every 12 equity shares held
  • Record Date: November 11, 2026

Payment Schedule

| Due Date | Face Value (₹) | Premium (₹) | Total (₹) | % of Issue Price |

| On Application | 3.75 | 641.25 | 645.00 | 75% |

| First and Final Call | 1.25 | 213.75 | 215.00 | 25% |

| Total | 5.00 | 855.00 | 860.00 | 100% |

Issue Timeline

  • Last date for credit of Rights Entitlements: November 12, 2026
  • Issue Opening Date: November 19, 2026
  • Last date for on-market renunciation: November 27, 2026
  • Issue Closing Date: December 3, 2026
  • Finalization of Basis of Allotment: December 4, 2026
  • Credit of Shares: December 7, 2026
  • Listing Date: December 9, 2026

Objects of the Issue

  • Repayment/prepayment of outstanding borrowings: ₹800 crore (90.9% of net proceeds)
  • General corporate purposes: ₹79.4 crore (9.1% of net proceeds)

The identified loan for repayment is from ICICI Bank Limited (₹800 crore sanctioned, fully drawn as of September 30, 2026) with interest rate of 8.40% per annum.

Capital Structure Impact

  • Pre-issue capital: 24,690,797 equity shares (₹123.45 million)
  • Post-issue capital: 34,978,629 equity shares (₹174.89 million) assuming full subscription
  • Dilution: Approximately 29.4% increase in share capital

Parties Involved

  • Registrar to Issue: MUFG Intime India Private Limited (formerly Link Intime India Private Limited)
  • Banker to Issue: ICICI Bank Limited
  • Monitoring Agency: CARE Ratings Limited
  • Designated Stock Exchange: BSE Limited
  • Legal Advisor: Shardul Amarchand Mangaldas & Co
  • Statutory Auditor: B S R & Co. LLP

Financial Information

  • Revenue from operations: ₹3,543.3 million (FY2026), ₹3,562.7 million (FY2025)
  • Profit after tax: ₹931.8 million (FY2026), ₹1,009.0 million (FY2025)
  • Six-month revenue (Sept 2026): ₹1,598.6 million
  • Six-month profit/(loss) (Sept 2026): (₹453.3) million

Risk Factors Disclosed

The document contains 50 risk factors including regulatory compliance risks, manufacturing dependence on third parties, competitive market environment, recent change in control and management, and foreign investment restrictions.

Corporate Background

The company was incorporated on December 13, 1947 as Ciba Pharma Private Limited and has undergone several name changes, most recently from Novartis India Limited to Evonile Pharma Limited effective October 1, 2026 following change in control.

Promoters

Current promoters are WaveRise Investments Limited and ChrysCapital Fund X, who acquired control from erstwhile promoter Novartis AG in July 2026.

Listing Arrangements

The company has received in-principle approval from BSE for listing of rights equity shares. Existing equity shares are listed on BSE and permitted to trade on NSE.

Other Material Information

  • The company does not own manufacturing facilities and operates an asset-light model
  • Recent acquisitions include Minipress brand for cardiology segment
  • Exclusive distribution agreement with Novartis Healthcare for ophthalmology products
  • No manufacturing facilities owned - relies on third-party manufacturers
  • Materiality threshold: ₹46.55 million